Reata Pharmaceuticals

💊 Neuropharmaceuticals· 📍 Dallas, TX, USA

Overview

Reata Pharmaceuticals developed omaveloxolone (Skyclarys), the first FDA-approved treatment for Friedreich's ataxia, acting as an Nrf2 activator to reduce oxidative stress in neuronal mitochondria.

More in Neuropharmaceuticals

Neurogenix Therapeutics

Basel, Switzerland

Acadia Pharmaceuticals

San Diego, USA

Acer Therapeutics

Newton, MA, USA

Praxis Precision Medicine

Cambridge, MA, USA

Axsome Therapeutics

New York, USA

BioXcel Therapeutics

New Haven, CT, USA

Latest industry news

It's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments

2026-06-23 · Product

MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy

2026-06-13 · Research

Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings

2026-06-11 · Product

Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial

2026-06-09 · Industry

Company details

Is this your company?

Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.

Claim & upgrade listing

Advertise

Reach neurotech professionals

Newsletter sponsorships, featured listings, and sponsored articles.

View packages →